Currax Pharmaceuticals has launched cost-saving initiative with GoodRx to expand access to Contrave, Currax’s branded oral non-GLP-1 weight loss medication.
The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance. Patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States.
Contrave is an extended release fixed-dose combination of two FDA-approved drugs, naltrexone and bupropion. Naltrexone is approved to treat alcohol and opioid dependence; Bupropion is approved to treat depression and seasonal affective disorder and as an aid to smoking cessation treatment.
Contrave was first approved in 2014 for use in adults with obesity or overweight who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.